BRAF and melanoma: The emergence of more effective therapies, such as immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) and targeted treatments (e.g., B-Raf inhibitors), has shifted the clinical approach to melanoma, offering improved survival, higher response rates, and fewer adverse effects, especially in advanced stages [4].